Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 August 2023 | Story The Conversation | Photo supplied
Claudia Ntsapi
Dr Claudia Ntsapi, Basic Medical Sciences Lecturer at the University of the Free State.

Opinion article by , Basic Medical Sciences Lecturer


As the world population has grown older, Alzheimer’s disease has become increasingly common. Alzheimer’s disease is the most prevalent form of dementia. Dementia is a term used to describe a range of symptoms linked to the decline in brain function with age. Symptoms include memory loss, communication difficulties, problem-solving struggles, and personality or behavioural changes.

Alzheimer’s disease is an increasingly urgent global issue. The World Health Organization predicts that the number of people with the condition will triple by 2050.

Despite this growing problem, Alzheimer’s disease remains a relatively understudied condition. This is particularly the case in sub-Saharan countries such as South Africa. One major challenge is that Alzheimer’s is a complex condition with no known cure. However, researchers have identified several key risk factors associated with the disease. These include age, genetics, lifestyle factors and underlying medical conditions.

In recent years, one of the most promising areas of research on age-related diseases, such as Alzheimer’s disease, has been the accumulation of harmful proteins in the brain. Specifically amyloid-ß. Amyloid-ß has remained a prominent area of research in Alzheimer’s disease as its build-up is a classic feature in the development of the condition. Understanding its involvement in the disease process is crucial for advancing our knowledge and developing effective strategies to diagnose, prevent and treat the disease.

The accumulation of amyloid-ß can lead to the formation of plaques. These plaques can interfere with communication between brain cells. This ultimately contributes to cognitive decline and other symptoms associated with Alzheimer’s disease.

Amyloid-ß is a large membrane protein that is essential in neural growth and repair. But its corrupted form in later life can destroy nerve cells. This triggers the loss of thought and memory that is associated with Alzheimer’s.

We therefore sought to find out if dietary interventions, particularly intermittent fasting, would counteract the accumulation of amyloid-ß in the brain and potentially safeguard against age-related brain cell death.

In a paper published in 2021, my colleague and I showed that in experiments conducted in mice we found that intermittent fasting counteracted amyloid-ß accumulation in the brain. These findings were further confirmed in a paper published in May of 2022.

Our findings are an important contribution to the search for the potential role of dietary interventions and are consistent with previous studies supporting the idea that intermittent fasting may help counteract amyloid-ß accumulation in the brain and protect against age-related brain cell death. To my knowledge, the most recent study using a variation of intermittent fasting, was published in September 2022. The clinical branch of this study remains ongoing.

Research into the causes of Alzheimer’s has gathered pace in recent years with new ground being broken on a regular basis as scientists search for treatments.

Our study’s findings suggest that intermittent fasting may be an effective way to increase the efficiency of autophagy – the process that breaks down and recycles damaged or unnecessary cellular components, such as organelles and toxic proteins. This process can therefore reduce the risk of amyloid-ß build-up and associated brain cell death.

These findings are particularly significant because they shed light on the relationship between autophagy and the death of brain cells with age, and the potential therapeutic benefits of interventions that target this process.

How it works

Intermittent fasting is a dietary approach that involves regulating food intake by alternating periods of fasting and eating. This dietary regimen comprises periods of restricted food consumption, followed by periods of normal eating.

There are different types of intermittent fasting. One is time-restricted eating, where food is consumed within a specific time window each day. Alternate-day fasting is where food is restricted every other day.

Intermittent fasting has been shown to have various health benefits. Some of the benefits relate to the promotion of brain health.

Our study’s findings suggest that intermittent fasting may be an effective way to increase the efficiency of autophagy, an essential process for removing toxic or misfolded proteins that can build up in cells.

Sometimes autophagy doesn’t work properly to remove harmful proteins or other cellular components from cells. This has been strongly implicated in the development and progression of various age-related diseases, and is a target of research for potential therapies.

What we did

In our study we investigated the effects of intermittent fasting on brain cells in mice, and brain cells isolated from mice with increased amyloid-ß toxicity. Mice cells are frequently used as a model for human cells in scientific research. This is because of the significant genetic similarity between mice and humans. This use of animal models allows researchers to gain valuable insights and test hypotheses. It is generally considered ethically preferable before potentially conducting human studies.

We found that 24 to 48 hours of intermittent fasting by mice provided protection against cell death in specific regions of their brain. We noted increased autophagy levels in cells of fasted mice. Even in the presence of a high amyloid-ß protein load in brain cells, intermittent fasting maintained autophagy activity. And the process remained effective over a 21-day treatment intervention period.

By increasing the efficiency of autophagy, it is possible to maintain the removal of harmful proteins in cells, even as we age.

The findings of this study suggest that interventions such as intermittent fasting could potentially protect against the development of age-related diseases. This has important implications for public health.

Intermittent fasting is a relatively simple dietary intervention: it’s easy to do. It has the potential to be widely adopted as a preventive measure against the onset of age-related diseases. These findings also provide a basis for future research into the mechanisms by which intermittent fasting protects against brain cell death, exploring the potential for additional therapeutic interventions that target autophagy, and examining the effects of different fasting regimens on brain health.The Conversation

This article is republished from The Conversation under a Creative Commons license. Read the original article.

News Archive

UFS Council unanimously reappoints Dr Khotso Mokhele as Chancellor
2015-04-02

 

Dr Khotso Mokhele, Chancellor of the University of the Free State

The Council of the University of the Free State (UFS) unanimously reappointed Dr Khotso Mokhele as Chancellor during its quarterly meeting held on 13 March 2015. He was first appointed in this portfolio by the Council on 4 June 2010.

“It is an honour for the Council to reappoint someone of this stature as Chancellor of the UFS. With his solid academic background and high profile in the business world, Dr Mokhele has been a great asset to the UFS. On behalf of the Council and the university community, I extend a word of appreciation for the work he has done during his first term as Chancellor of the UFS. He is an exceptional leader, and the university community is looking forward to have him as Chancellor for a second term,” said Judge Ian van der Merwe, Chairperson of the UFS Council.

Dr Mokhele was awarded a BSc Agriculture from Fort Hare University, and continued his studies at the University of California Davis (USA) on the Fulbright-Hays Scholarship Programme, completing his MSc (Food Science) and PhD (Microbiology). He was subsequently a postdoctoral fellow at Johns Hopkins University School of Medicine (USA) and the University of Pennsylvania School of Medicine (USA). Dr Mokhele is the recipient of honorary doctorates from nine South African universities including the UFS, and from Rutgers University in the USA.

He was Chairman of the Rhodes Scholarship Selection Committee for Botswana, Malawi, Namibia, Lesotho and Swaziland (2007-2011), and served on the South Africa at Large Rhodes Scholarship Selection Committee for more than 10 years. As President and Chief Executive Officer (CEO) of the Foundation for Research Development (1996-1999) and the NRF from 1999 to 2006, Dr Mokhele played a central role in providing visionary and strategic direction to the South African science system. He was the Founder President of the Academy of Science of South Africa (ASSAf), Founder President and CEO of the National Research Foundation (NRF), Chairperson of the Economic Advisory Council to the Premier of the Free State (2001-2004), and a member of the Advisory Council on Innovation to the Minister of Science and Technology (2003-2007). His role in securing government and international support for the Southern African Large Telescope Project (SALT) is evidence of his dedication to science in South Africa. The success of this project laid the basis for South Africa being selected to host more than 70% of the Square Kilometre Array, an international mega telescope for radio astronomy.

In recognition of his contribution to the development of science, he was the recipient of the Technology Top 100 Lifetime Achievers Award in 2009 and the National Science and Technology Forum Award in 2005. His role in science is recognised internationally. He was an elected Vice-President: Scientific Planning and Review of the International Council for Science and Chairperson of its Committee for Scientific Planning and Review (2005-2008) as well as a member of the Committee on Developing and Transition Economy Countries of the International Social Science Council (2008-2010). He also represented South Africa on the executive board of UNESCO, and was awarded the Member Legion of Honour of the Republic of France for his work in strengthening scientific ties between South Africa and France.

Dr Mokhele currently serves as Special Advisor to the Minister of Science and Technology, the Honourable Naledi Pandor. His current corporate positions include: Non-Executive Chairman: Board of Directors, Impala Platinum Holdings Ltd (Implats); Lead Independent Non-Executive Director: African Oxygen Ltd (Afrox); Non-Executive Director of Zimbabwe Platinum Holdings Ltd (Zimplats); Hans Merensky Holdings Ltd; and Tiger Brands Ltd. He is the President of the Hans Merensky Foundation (South Africa) and a Trustee of SciDev.Net (a web-based scientific magazine based in London, UK) and Start International Inc (USA).

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept